New patentable leads

You select any kinase target and we deliver the novel, patentable, sub-micromolar lead compound.

Based on our NCL, Masterkey and scaffold hopping technologies, in a year from the time we have set up the biochemical kinase assay we can deliver a novel patentable submicromolar kinase inhibitory lead compound.

Using our unique kinase inhibitor NCL library we always have a good hit rate.

Depending on the patentability of the hits we do Master Key modifications and pharmacophore modeling and if necessary scaffold hopping and hit to lead optimization and in 4-5 research cycles we deliver the patentable sub-micromolar lead structures.